Literature DB >> 8769567

Identification of novel mRNA isoforms for human DNA polymerase beta.

Y J Chyan1, P R Strauss, T G Wood, S H Wilson.   

Abstract

Recently, we reported the organization of the thirteen exons of the human DNA polymerase beta (beta-pol) gene and the sequences of the exon-intron junctions. Splice variants of human beta-pol mRNA have been postulated to be related to cancer development. Here, we report the characterization of isoforms of human beta-pol mRNA in different cells by reverse transcription polymerase chain reaction (RT-PCR). DNA sequence analysis of RT-PCR products revealed eight alternative splicing mRNA isoforms in the brain cancer cell line, SK-N-MC. These various isoforms were consistent with alternative splicing of four exons (II, IV, V, and VI) and with a 105-nucleotide insertion (exon alpha) between exons VI and VII. We also found an isoform with a 19-nucleotide sequence inserted into the exon IV and V junction, which resulted from usage of a different 3' splice site. Seven of the isoforms resulted in truncated open reading frame (ORF); five corresponded to deduced peptide of amino acids 1-20 of beta-pol and two corresponded to amino acids 1-60 of beta-pol. Only one of the right mRNA isoforms, that with the exon alpha insertion, was in-frame with the entire wild-type ORF resulting in a deduced protein of 370 residues, compared with the wild-type protein of 335 residues and 39 kD. This longer ORF was shown to be capable of encoding a beta-pol protein, larger than wild-type beta-pol, that cross-reacted with beta-pol antibody and exhibited beta-pol enzymatic activity. The mRNA isoform with the exon alpha insertion was not tumor specific because it as detected in low abundance in all cells tested, except the colon cell line CCD18 Co where the isoform was absent. The genomic location of exon alpha is in intron VI, 990 bp upstream of exon VII and flanked by consensus splice sites. Thus, this 105-bp genomic sequence is a beta-pol exon present in a low-abundance beta-pol mRNA isoform capable of encoding an approximately 42-kD beta-pol.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8769567     DOI: 10.1089/dna.1996.15.653

Source DB:  PubMed          Journal:  DNA Cell Biol        ISSN: 1044-5498            Impact factor:   3.311


  7 in total

1.  Two novel human and mouse DNA polymerases of the polX family.

Authors:  S Aoufouchi; E Flatter; A Dahan; A Faili; B Bertocci; S Storck; F Delbos; L Cocea; N Gupta; J C Weill; C A Reynaud
Journal:  Nucleic Acids Res       Date:  2000-09-15       Impact factor: 16.971

2.  The adaptive significance of unproductive alternative splicing in primates.

Authors:  Adonis Skandalis; Mark Frampton; Jon Seger; Miriam H Richards
Journal:  RNA       Date:  2010-08-18       Impact factor: 4.942

3.  Characterization of DNA polymerase beta splicing variants in gastric cancer: the most frequent exon 2-deleted isoform is a non-coding RNA.

Authors:  Valeria Simonelli; Mariarosaria D'Errico; Domenico Palli; Rajendra Prasad; Samuel H Wilson; Eugenia Dogliotti
Journal:  Mutat Res       Date:  2009-07-25       Impact factor: 2.433

4.  Structural organization and splice variants of the POLE1 gene encoding the catalytic subunit of human DNA polymerase epsilon.

Authors:  D Huang; H Pospiech; T Kesti; J E Syväoja
Journal:  Biochem J       Date:  1999-05-01       Impact factor: 3.857

5.  A survey of splice variants of the human hypoxanthine phosphoribosyl transferase and DNA polymerase beta genes: products of alternative or aberrant splicing?

Authors:  Adonis Skandalis; Elke Uribe
Journal:  Nucleic Acids Res       Date:  2004-12-15       Impact factor: 16.971

6.  Heterogeneity in expression of DNA polymerase beta and DNA repair activity in human tumor cell lines.

Authors:  Nandan Bhattacharyya; Huan-Chao Chen; Liming Wang; Spira Banerjee
Journal:  Gene Expr       Date:  2002

7.  The Pol β variant containing exon α is deficient in DNA polymerase but has full dRP lyase activity.

Authors:  Da-Peng Dai; Rajendra Prasad; Phyllis R Strauss; Samuel H Wilson
Journal:  Sci Rep       Date:  2019-07-09       Impact factor: 4.379

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.